Literature DB >> 22939992

Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status.

Margaret Haney1, Gillinder Bedi, Ziva D Cooper, Andrew Glass, Suzanne K Vosburg, Sandra D Comer, Richard W Foltin.   

Abstract

BACKGROUND: Few marijuana smokers in treatment achieve sustained abstinence, yet factors contributing to high relapse rates are unknown.
METHODS: Study 1: data from five inpatient laboratory studies assessing marijuana intoxication, withdrawal, and relapse were combined to assess factors predicting the likelihood and severity of relapse. Daily, nontreatment-seeking marijuana smokers (n = 51; 10 ± 5 marijuana cigarettes/day) were enrolled. Study 2: to isolate the effects of cigarette smoking, marijuana intoxication, withdrawal, and relapse were assessed in daily marijuana and cigarette smokers (n = 15) under two within-subject, counter-balanced conditions: while smoking tobacco cigarettes as usual (SAU), and after at least 5 days without cigarettes (Quit).
RESULTS: Study 1: 49% of participants relapsed the first day active marijuana became available. Tobacco cigarette smokers (75%), who were not abstaining from cigarettes, were far more likely to relapse than non-cigarette smokers (odds ratio: 19, p < .01). Individuals experiencing more positive subjective effects (i.e., feeling "high") after marijuana administration and those with more negative affect and sleep disruption during marijuana withdrawal were more likely to have severe relapse episodes (p < .05). Study 2: most participants (>87%) relapsed to marijuana whether in the SAU or Quit phase. Tobacco cigarette smoking did not significantly influence relapse, nor did it affect marijuana intoxication or most symptoms of withdrawal relative to tobacco cessation.
CONCLUSIONS: Daily marijuana smokers who also smoke cigarettes have high rates of marijuana relapse, and cigarette smoking versus recent abstinence does not directly influence this association. These data indicate that current cigarette smoking is a clinically important marker for increased risk of marijuana relapse.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22939992      PMCID: PMC3522776          DOI: 10.1016/j.biopsych.2012.07.028

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  56 in total

1.  Brief treatments for cannabis dependence: findings from a randomized multisite trial.

Authors: 
Journal:  J Consult Clin Psychol       Date:  2004-06

2.  A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery.

Authors:  Judith J Prochaska; Kevin Delucchi; Sharon M Hall
Journal:  J Consult Clin Psychol       Date:  2004-12

3.  Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence.

Authors:  Alan J Budney; Brent A Moore; Heath L Rocha; Stephen T Higgins
Journal:  J Consult Clin Psychol       Date:  2006-04

4.  Contingency management for tobacco smoking in methadone-maintained opiate addicts.

Authors:  S Shoptaw; M E Jarvik; W Ling; R A Rawson
Journal:  Addict Behav       Date:  1996 May-Jun       Impact factor: 3.913

5.  A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.

Authors:  Ziva D Cooper; Richard W Foltin; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Margaret Haney
Journal:  Addict Biol       Date:  2012-06-28       Impact factor: 4.280

6.  Transdermal nicotine alters some of marihuana's effects in male and female volunteers.

Authors:  David M Penetar; Elena M Kouri; Michelle M Gross; Elissa M McCarthy; Christina K Rhee; Erica N Peters; Scott E Lukas
Journal:  Drug Alcohol Depend       Date:  2005-03-04       Impact factor: 4.492

7.  Abstinence symptoms following smoked marijuana in humans.

Authors:  M Haney; A S Ward; S D Comer; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  1999-02       Impact factor: 4.530

8.  Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory.

Authors:  R W Foltin; M Haney; S D Comer; M W Fischman
Journal:  Physiol Behav       Date:  1996-02

9.  Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.

Authors:  Graciela N Balerio; Ester Aso; Fernando Berrendero; Patricia Murtra; Rafael Maldonado
Journal:  Eur J Neurosci       Date:  2004-11       Impact factor: 3.386

10.  The mental health risks of adolescent cannabis use.

Authors:  Wayne Hall
Journal:  PLoS Med       Date:  2006-01-24       Impact factor: 11.069

View more
  57 in total

Review 1.  An overview of alcohol and tobacco/nicotine interactions in the human laboratory.

Authors:  Terril L Verplaetse; Sherry A McKee
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-20       Impact factor: 3.829

2.  Precipitated Δ9-THC withdrawal reduces motivation for sucrose reinforcement in mice.

Authors:  M L Eckard; K R Trexler; B T Kotson; K G Anderson; S G Kinsey
Journal:  Pharmacol Biochem Behav       Date:  2020-06-09       Impact factor: 3.533

3.  Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.

Authors:  Erin A McClure; Nathaniel L Baker; Susan C Sonne; Udi E Ghitza; Rachel L Tomko; LaTrice Montgomery; Shanna Babalonis; Garth E Terry; Kevin M Gray
Journal:  Drug Alcohol Depend       Date:  2018-08-25       Impact factor: 4.492

4.  Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.

Authors:  Margaret Haney; Ziva D Cooper; Gillinder Bedi; Evan Herrmann; Sandra D Comer; Stephanie Collins Reed; Richard W Foltin; Frances R Levin
Journal:  Addict Biol       Date:  2018-04-16       Impact factor: 4.280

5.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

6.  Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use.

Authors:  Tangeria R Adams; Julia H Arnsten; Yuming Ning; Shadi Nahvi
Journal:  J Psychoactive Drugs       Date:  2017-09-27

7.  Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.

Authors:  Evan S Herrmann; Ziva D Cooper; Gillinder Bedi; Divya Ramesh; Stephanie C Reed; Sandra D Comer; Richard W Foltin; Margaret Haney
Journal:  Psychopharmacology (Berl)       Date:  2016-04-16       Impact factor: 4.530

8.  The influence of cannabis motives on alcohol, cannabis, and tobacco use among treatment-seeking cigarette smokers.

Authors:  Dawn W Foster; Nicholas P Allan; Michael J Zvolensky; Norman B Schmidt
Journal:  Drug Alcohol Depend       Date:  2014-11-26       Impact factor: 4.492

9.  Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.

Authors:  Kristen R Trexler; Sara R Nass; Molly S Crowe; Joshua D Gross; Margaret S Jones; Austin W McKitrick; David P Siderovski; Steven G Kinsey
Journal:  Drug Alcohol Depend       Date:  2018-07-07       Impact factor: 4.492

10.  Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.

Authors:  Margaret Haney; Ziva D Cooper; Gillinder Bedi; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2013-02-26       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.